Linozid 600 mg tablet is a medicine made by Orion Pharma Ltd. Doctors use Linezolid for certain serious bacterial infections, such as infections caused by vancomycin-resistant Enterococcus faecium, including when bacteria are present in the blood, and hospital-acquired pneumonia caused by particular bacteria.
There are 39 brands of Linezolid listed in Bangladesh. 5 of them have a lower unit price than Linozid. The lowest listed price is Linez 400 mg Tablet at ৳ 60.00 per unit.
What is Linozid 600 mg Tablet?
Linozid 600 mg is a tablet product of Orion Pharma Ltd. that contains Linezolid. This medicine should only be used under a doctor's supervision, and the dose and course are decided by the doctor. Linozid tablet 600 mg contains Linezolid, an antibiotic that belongs to the oxazolidinone group. Use it only as your doctor directs.
Uses of Linozid
Doctors use Linezolid for certain serious bacterial infections, such as infections caused by vancomycin-resistant Enterococcus faecium, including when bacteria are present in the blood, and hospital-acquired pneumonia caused by particular bacteria. Do not use it for common illnesses such as colds, and do not use it on your own. The doctor will decide if Linozid is appropriate for the infection.
How to use Linozid
Keep the medicine out of reach of children and store it at room temperature, away from light and moisture. Linozid is taken by mouth. Swallow the tablet with water. Take Linozid tablet exactly as your doctor tells you. Do not change the dose or stop treatment early, even if you feel better, because doing so can make the infection harder to treat. Do not change the dose or stop taking it early, even if you feel better, because stopping too soon can allow the infection to return or worsen.
Side effects of Linozid
Get medical help straight away if you have repeated vomiting, unusual tiredness, or signs of an allergic reaction such as rash or swelling. Most side effects reported with Linozidolid are mild to moderate. Tell the doctor if you notice unusual nausea or vomiting, or any effect that worries you. Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
It is also not for people with uncontrolled high blood pressure, pheochromocytoma, thyrotoxicosis, or carcinoid syndrome. Pregnancy category C: use only if the potential benefit justifies the risk to the fetus. Always consult your doctor first. Tell your doctor about all other medicines you take, because Linozidolid can interact with some medicines, including certain ones for mood and certain ones that raise blood pressure.
Frequently asked questions
What is Linozid used for?
Doctors use Linezolid for certain serious bacterial infections, such as infections caused by vancomycin-resistant Enterococcus faecium, including when bacteria are present in the blood, and hospital-acquired pneumonia caused by particular bacteria. Do not use it for common illnesses such as colds, and do not use it on your own.
How is Linozid used?
Keep the medicine out of reach of children and store it at room temperature, away from light and moisture. Linozid is taken by mouth.
What are the side effects of Linozid?
Get medical help straight away if you have repeated vomiting, unusual tiredness, or signs of an allergic reaction such as rash or swelling. Most side effects reported with Linozidolid are mild to moderate.
Can I use Linozid in pregnancy or while breastfeeding?
It is also not for people with uncontrolled high blood pressure, pheochromocytoma, thyrotoxicosis, or carcinoid syndrome. Pregnancy category C: use only if the potential benefit justifies the risk to the fetus.
Vancomycin-Resistant Enterococcus faecium infections including cases with concurrent bacteremia.
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae (including multi-drug resistant strains). Combination therapy ... Read moreVancomycin-Resistant Enterococcus faecium infections including cases with concurrent bacteremia.
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae (including multi-drug resistant strains). Combination therapy may be clinically indicated if the documented or presumptive pathogens include Gram-negative organism.
Complicated skin and skin structure infections, including diabetic foot infections (without concomitant osteomyelitis) caused by Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes or Streptococcus agalactiae.
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes.
Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains) including cases with concurrent bacteremia or Staphylococcus aureus (methicillin-susceptible strains only).
Pharmacology
Linezolid is a synthetic, antibacterial agent belonging to a new class of antibiotics, the oxazolidinones, with in vitro activity against Gram positive aerobic bacteria, some Gram positive anaerobic bacteria and certain Gram negative bacteria. It selectively inhibits bacterial protein synthesis via a mechanism of action different from that of other antibacterial agents. Linezolid binds to the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome and prevents the formation of a functional 70S initiation complex which is an essential component of the bacterial translation process. The results of time-kill studies have shown Linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, Linezolid was found to be bactericidal for the majority of strains.
Dosage & Administration
Patients who commence treatment on the parenteral formulation may be switched to oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as Linezolid has an oral bioavailability of approximately 100%. The injection should be administered over a period of 30 to 120 minutes. The film-coated tablets or oral suspension may be taken with or without food.
Complicated skin and skin structure infections, Community-acquired pneumonia, including concurrent bacteremia-
Pediatric Patients (Birth through 11 Years of Age): 10 mg/kg IV or oral t.i.d.
Adults and Adolescents (12 Years and Older): 600 mg IV or oral b.i.d.
Recommended Duration of Treatment (consecutive days): 10 to 14
Nosocomial pneumonia, Vancomycin-resistant Enterococcus faecium infections including concurrent bacteremia-
Pediatric Patients (Birth through 11 Years of Age): 10 mg/kg IV or oral t.i.d.
Adults and Adolescents (12 Years and Older): 600 mg IV or oral b.i.d.
Recommended Duration of Treatment (consecutive days): 14 to 28
Uncomplicated skin and skin structure infections-
Pediatric Patients (Birth through 11 Years of Age): <5 yrs: 10 mg/kg oral t.i.d. 5-11 yrs: 10 mg/kg oral b.i.d
Adults and Adolescents (12 Years and Older): Adults: 400 mg oral b.i.d. Adolescents: 600 mg oral b.i.d
Recommended Duration of Treatment (consecutive days): 10 to 14
Neonates <7 days: Most pre-term neonates <7 days of age (gestational age <34 weeks) have lower systemic Linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.
Interaction
Monoamine Oxidase Inhibition: Linezolid is a reversible and nonselective inhibitor of monoamine oxidase. Therefore, Linezolid has the potential for interaction with adrenergic and serotonergic agents.
Adrenergic Agents: Some individuals receiving Linezolid may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Initial doses of adrenergic agents such as dopamine or epinephrine should be reduced and titrated to achieve the desired response.
Serotonergic Agents: Physicians should be alert to the possible signs and symptoms of serotonergic syndrome in patients receiving concomitant Linezolid and serotonergic agents.
Contraindications
Linezolid formulations are contraindicated for using in patients who have known hypersensitivity to Linezolid or any of the other product components. Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. Phenelzine, Isocarboxazid) or within two weeks of taking any such medicinal product. Linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome and/or patients taking directly and indirectly acting sympathomimetic agents (e.g. Pseudoephedrine), vasopressive agents (e.g. Epinephrine, Norepinephrine), dopaminergic agents (e.g. Dopamine, Dobutamine), serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone.
Side Effects
Most of the adverse events reported with Linezolid were mild to moderate in intensity. The most common adverse events in patients treated with Linezolid were diarrhea, headache and nausea. Other adverse events includes oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Linezolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Linezolid is excreted in human milk. Because many drugs are excreted in human milk. Caution should be exercised when Linezolid is administered to a nursing woman.
Precautions & Warnings
Patients who develop recurrent nausea or vomiting, unexplained acidosis or low bicarbonate level while receiving Linezolid should receive immediate medical evaluation. Where administration of Linezolid and concomitant serotonergic agents are clinically appropriate, patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia and incoordination. If signs or symptoms occur, physicians should consider discontinuation of either one or both agents. If the concomitant serotonergic agent is withdrawn, discontinuation symptoms can be observed. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision or visual field defect, prompt ophthalmic evaluation is recommended. Convulsions have been reported in patients when treated with Linezolid. In some of these cases, a history of seizures or risk factors for seizures was reported.
Overdose Effects
No cases of overdose have been reported. Symptomatic and supportive care is advised together with maintenance of glomerular filtration. Approximately 30% of a Linezolid dose is removed during 3 hours of haemodialysis. No data are available for the removal of Linezolid by peritoneal dialysis or haemoperfusion.
Storage Conditions
Linezolid formulations should be stored at room temperature (15°C-30°C), away from light and moisture. All medicines should be kept away from children.
Alternative brands of Linezolid
Other brands with the same generic name, cheapest first.